This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
What good is AI in healthcare if it doesn’t improve financial margins? The question is getting posed in the C-suites of provider organizations and insurance companies.
Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.
The new platform provides users with real-time access to high-quality electrocardiograms and patient data. The goal is to ensure everyone is on the same page at all times, with no unnecessary delays.
The annual list is based on resources, services provided, outcomes data and survey responses from thousands of physicians. Did your facility make the cut?
Hospitals should be making every effort to help sonographers deliver better, more accurate echocardiograms and improve the diagnosis of severe aortic stenosis. If you take care of your sonographers, your sonographers will take care of you.
Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.
At a time when patient assaults against nurses are reportedly on the rise, cases that invert the equation only reinforce the public’s perception that hospitals are chaotic places.
“We can reach tissues, bones and organs with high spatial precision that haven’t been reachable with light-based printing methods," one researcher explained.
The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent.
In its annual outlook report released this week, Fitch Ratings says the coming calendar year will probably strike much of the sector as “another make or break” period.